8-K: Lyell Immunopharma Issues 625,000 Shares Following Achievement of ImmPACT Bio Clinical Milestone

Lyell Immunopharma, Inc. announced the issuance of 625,000 common shares to ImmPACT Bio securityholders after a key clinical milestone for ImmPACT's next-generation CAR T-cell product candidate was achieved.

Summary

• Lyell Immunopharma, Inc. (Lyell) has issued 625,000 shares of its common stock to securityholders of ImmPACT Bio USA Inc. (ImmPACT).
• This issuance is a result of the achievement of a specific clinical milestone for ImmPACT's next-generation CAR T-cell product candidate.
• The shares are 'Equity Milestone Shares' as stipulated in the Merger Agreement dated October 24, 2024, for Lyell's acquisition of ImmPACT.
• The 625,000 shares reflect the Company's 1-for-20 reverse stock split, which was effective on May 30, 2025.
• The shares are being issued in a private placement, relying on the exemption provided by Section 4(a)(2) of the Securities Act of 1933.

Sentiment

Score: 7

Explanation: The achievement of a clinical milestone is a positive development for the company's pipeline, indicating progress in its R&D efforts. While there is some dilution from the share issuance, it is a pre-agreed term of the acquisition and signifies successful advancement of an acquired asset.

Positives

• Achievement of a clinical milestone for a next-generation CAR T-cell product candidate, indicating progress in the acquired ImmPACT Bio pipeline.
• Fulfillment of a contractual obligation from the ImmPACT Bio acquisition, demonstrating adherence to merger terms.

Negatives

• The issuance of 625,000 new shares will result in dilution for existing Lyell Immunopharma shareholders.

Risks

• The Equity Milestone Shares have not been registered under the Securities Act or any state securities laws, meaning their future sale in the United States would require registration or an applicable exemption.
• Potential for future sales of these unregistered shares by ImmPACT securityholders could create downward pressure on Lyell's stock price.

Future Outlook

The achievement of the clinical milestone for ImmPACT's next-generation CAR T-cell product candidate suggests continued progress in Lyell's pipeline, particularly in the advanced cell therapy domain acquired through the ImmPACT merger.

Management Comments

• The report was signed by Mark Meltz, General Counsel and Corporate Secretary of Lyell Immunopharma, Inc.

Industry Context

This announcement highlights ongoing activity in the CAR T-cell therapy space, a rapidly evolving area within biotechnology focused on developing advanced cell therapies for cancer. The successful achievement of a clinical milestone for a next-generation candidate underscores the continued R&D progress and potential for innovation in this competitive sector, where companies like Lyell are integrating acquired assets to expand their therapeutic pipelines.

Comparison to Industry Standards

• NA

Related Party Transactions

• The issuance of Equity Milestone Shares to ImmPACT securityholders is a transaction with parties who became related through the merger agreement, fulfilling a pre-existing contractual obligation.

Stakeholder Impact

• Shareholders: Experience dilution due to the issuance of 625,000 new shares.
• ImmPACT Securityholders: Will receive 625,000 shares of Lyell Common Stock, fulfilling their entitlement under the merger agreement.

Next Steps

• The Company will proceed with the issuance of 625,000 shares of Company Common Stock in a private placement to the ImmPACT securityholders, subject to adjustments for fractional shares.

Key Dates

Recommendation

Keywords

Lyell Immunopharma, ImmPACT Bio, CAR T-cell, clinical milestone, equity issuance, merger agreement, private placement, biotechnology, immunotherapy, SEC filing, 8-K